Confident Bayer Diagnostics could notch up +6% this year
This article was originally published in Clinica
Executive Summary
Bayer's healthcare division may have had a rocky year on three fronts - given its voluntary withdrawal of cholesterol-lowering drug Lipobay/Baycol, production and supply difficulties relating to the recombinant factor VIII vaccine Kogenate and the poor economic conditions - but its diagnostics division is bucking the depressed trend.